Fig. 1
Replicative fitness of seven patient-derived HIV-1 isolates in the absence of any host selective pressure, including antiretroviral drugs. a Seven HIV-1 isolates from 3 viremic non-progressor (VNP), 3 typical (TP) and one rapid (RP) progressor patients were evaluated for their ability to replicate in peripheral blood mononuclear cells (PBMC). Virus replication was quantified by measuring reverse transcriptase (RT) activity in the cell-free supernatant. b Viral replication slopes were calculated using the slopes between cpm values at days 0 and 4, 0 and 6, 0 and 8, 0 and 11, and 0 and 14. All five slope values for each virus were used to calculate the mean, standard deviation, and 10th and 90th percentiles. Differences in the mean values were calculated using a One Way Analysis of Variance test and the significance difference from the primary wild-type HIV-1B-92US076 control isolate calculated using the Bonferroni’s Multiple Comparison Test. c Each patient-derived HIV-1 isolate was competed against two different non-subtype B HIV-1 control strains (HIV-1A-92UG029 and HIV-1AE-CMU06) in PBMCs and their replicative fitness calculated and expressed as a percentage of the replicative fitness of the reference virus HIV-1B-92US076 (set as 100%) as described [28, 35, 66, 67]. Values represent results obtained from single growth competition experiments. Viral replication kinetics and growth competitions marked with an asterisk were significantly different to the HIV-1B-92US076 control (p < 0.05, 95% CI)